iPCV 22
Alternative Names: iPCV-22Latest Information Update: 10 Feb 2023
At a glance
- Originator Unknown
- Developer Aeolian Biotech
- Class Conjugate vaccines; Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Pneumococcal infections
Most Recent Events
- 10 Feb 2023 Aeolian Biotech has patents pending for pneumococcal vaccines
- 10 Feb 2023 Preclinical trials in Pneumococcal infections (In neonates, In children, In adolescents) in USA (unspecified route)
- 10 Feb 2023 Aeolian Biotech plans a phase III trial (In adults) for pneumococcal infections in the year 2027 (Aeolian Biotech pipeline, February 2023)